# US 2012/0252850 A1 · Niacin conjugated fatty acid mixtures and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252850 A1
- Document ID: US20120252850A1
- Status: Published application
- Kind: A1
- Application number: 13/437,643
- Filed: 2012-04-02
- Published: 2012-10-04
- Earliest claimed: 2009-09-01
- Assignees: Catabasis Pharmaceuticals, Inc.
- Inventors: Jill C. Milne; Michael R. Jirousek; Jean E. Bemis; Chi B. Vu
- Web page: https://patentgrep.com/patent/US20120252850A1

## CPC

- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/4406: only substituted in position 3, e.g. zimeldine (nicotinic acid A61K31/455)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/80: in position 3
- C07D 213/82: in position 3
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to niacin conjugated fatty acid mixtures; compositions comprising an effective amount of a niacin conjugated fatty acid mixture; and methods for treating or preventing an metabolic disorder comprising the administration of an effective amount of a niacin conjugated fatty acid mixture.

## Claims

### Claim 1

A pharmaceutical composition comprising a niacin conjugated fatty acid mixture.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the niacin conjugated fatty acids are N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)nicotinamide (I-7); and N-(2-(5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenamidoethyl)nicotinamide (I-8).

### Claim 3

A method of making a niacin conjugated fatty acid mixture the method comprising contacting a mixture of EPA and DHA, with a nicotinic acid derivative, and a linker.

### Claim 4 (depends on 3)

The method of claim 3, wherein the EPA and DHA are EPA ethyl ester and DHA is DHA ethyl ester.

### Claim 5 (depends on 3)

The method of claim 3, wherein the EPA and DHA are in the form of free acids.

### Claim 6 (depends on 3)

The method of claim 3, wherein the linker comprises two amino groups.

### Claim 7 (depends on 3)

The method of claim 3, wherein the linker comprises an amino group and a hydroxyl group.

### Claim 8 (depends on 3)

The method of claim 3, wherein the ratio of EPA to DHA is between about 25:75 to about 75:25.

### Claim 9 (depends on 3)

The method of claim 3, wherein the linker is selected from ethanolamine and ethylenediamine.

### Claim 10 (depends on 3)

The method of claim 3, wherein the niacin conjugated fatty acid mixture comprises:
N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)nicotinamide (I-7); and
N-(2-(5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenamidoethyl)nicotinamide (I-8).

### Claim 11

A method for treating or preventing a metabolic disorder comprising the administration of an effective amount of a niacin conjugated fatty acid mixture.

### Claim 12 (depends on 11)

The method of claim 11, wherein the niacin conjugated fatty acid mixture comprises:
N-(2-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamidoethyl)nicotinamide (I-7); and
N-(2-(5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenamidoethyl)nicotinamide (I-8).
